LEE'S PHARM.
李 氏 大 藥 廠

Lee's Pharmaceutical Holdings Limited
李氏大藥廠控股有限公司*

(incorporated in the Cayman Islands with limited liability)
(Stock Code: 950)

VOLUNTARY ANNOUNCEMENT
FUNDING APPROVED FOR SYNTHETIC SURFACTANT PROJECT

This announcement is made by the board (the "**Board**") of directors (the "**Directors**") of Lee's Pharmaceutical Holdings Limited (the "**Company**" or "**Lee's Pharm**", together with its subsidiaries, the "**Group**") on a voluntary basis.

The Board of the Company is pleased to announce that Lee's Pharm will receive financial funding from the Gates Foundation to support the Group's synthetic surfactant project.

The short-term objective of this supported project is to successfully complete the active pharmaceutical ingredient (API) and formulation research and development, as well as the manufacturing processes for the drug. The ultimate goal is to bring this life-saving medication to low- and middle-income countries at an affordable price, specifically to help premature infants suffering from respiratory distress syndrome.

The Board considers that this funding support from the Gates Foundation is highly aligned with the Company's strategic focus on paediatrics and rare diseases. It reinforces the Group's ongoing commitment to global healthcare accessibility and utilizing its innovative drug delivery platforms to address critical unmet medical needs.

* *For identification purpose only*

ABOUT LEE'S PHARM

The Company is a research-driven and market-oriented biopharmaceutical company with more than 30 years' experience in the pharmaceutical industry in China. The Company is fully integrated with solid infrastructures in drug development, clinical development, regulatory, manufacturing, sales and marketing based in Mainland China with global perspectives. The Company has established extensive partnerships with numerous international companies in the U.S., Europe, and Asia, and currently markets over 25 proprietary, generic and licensed-in pharmaceutical products in Mainland China, Hong Kong, Macau and Taiwan. The Company focuses on several key therapeutic areas such as cardiovascular health, woman's health, paediatrics, rare diseases, oncology, dermatology and obstetrics. In addition, the Company has recently acquired U.S.-based assets in line with its strategy to broaden its portfolio of innovative drug delivery technologies covering a wide range of indications and reinforcing the Company's global expansion strategy. More information is available at www.leespharm.com.

By order of the Board
Lee's Pharmaceutical Holdings Limited
Lee Siu Fong
Chairman

Hong Kong, 1 June 2026

As at the date of this announcement, Ms. Lee Siu Fong (Chairman) and Ms. Leelalertsuphakun Wanee are executive Directors, Dr. Li Xiaoyi, Mr. James Charles Gale and Mr. Huang Zuie-Chin are non-executive Directors, Dr. Chan Yau Ching, Bob, Ms. Cheang Yee Wah, Eva and Dr. Tsim Wah Keung, Karl are independent non-executive Directors.